Meningococcal (muh-nin-jo-cok-ul) disease is a serious bacterial infection that most often leads to severe swelling of the tissues surrounding the brain and spinal cord (meningitis) or infection of the bloodstream (meningococcemia). Even with treatment, approximately one out of every 10 people who get meningococcal disease will die; of those who survive, about two in 10 will have permanent problems including brain damage, kidney damage, hearing loss, or amputation of arms, legs, fingers, or toes.
NFID is committed to increasing awareness about meningococcal disease among consumers and healthcare professionals and to prevention of meningococcal disease through vaccination.
NFID report examining the public health response to the recent outbreaks and strategies for appropriate and streamlined public health
responses to future outbreaks
National Foundation for Infectious Diseases (NFID)
Centers for Disease Control and Prevention (CDC)
American Academy of Pediatrics (AAP)
Centers for Disease Control and Prevention (CDC): Routine vaccination with a quadrivalent vaccine that protects against meningococcal serogroups A, C, W, and Y is recommended for all adolescents at age 11-12 years with a booster dose at age 16 years
Centers for Disease Control and Prevention (CDC): Meningococcal serogroup B vaccination may be recommended by healthcare professionals for certain individuals age 16-23 years, with a preferred age of 16-18 years
National Foundation for Infectious Disease (NFID)
Improving Rates in Adolescents and Reducing Racial, Ethnic, and Socioeconomic Disparities:
NFID Call to Action (July 2010)
National Foundation for Infectious Diseases
7201 Wisconsin Avenue
Bethesda, MD 20814
T: (301) 656-0003 | F: (301) 907-0878